Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. - Wikidata - wikimedia - TriplyDB

Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q38573559

about

Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy.Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure.Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data.Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin.Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus Metabolic ketoacidosis with normal blood glucose: A rare complication of sodium-glucose cotransporter 2 inhibitors.Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome.Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials.Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS).Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis.Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern.Canagliflozin: A Review in Type 2 Diabetes.Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.Canagliflozin lowers blood sugar, but does it also lower cardiovascular risk? Maybe not.An Indirect Comparison of Changes in the Impact of Weight on Quality of Life Among Subjects with Type 2 Diabetes Treated with Antihyperglycemic Agents in Dual Therapy with Metformin.Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes.Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled Trials.Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes.Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study.The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan.Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States.Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes.Characterization of Metabolic Parameters in Responders and Nonresponders Treated with Canagliflozin Monotherapy in Drug-naive Subjects with Type 2 Diabetes.Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use

P2860

Q26740253-425600C1-EA48-4F21-993F-86123DA2995F Q28072339-EFC465D8-48E6-42E5-A35A-B83650AC16D3 Q33665173-36E5FE3D-181B-489E-8C6A-35D38720D03C Q33815573-0189C42F-63B3-490D-909D-2DC383B64150 Q33887783-380DC06C-005F-4819-A9D1-0C75B2D1DD38 Q35903101-4BC84149-BBE4-41A2-8133-3960A094684A Q36317577-01A41484-310D-4153-9B8E-EFD4DF1A0F32 Q36989681-ACE126B7-787A-4588-9F55-081EF7F91B60 Q37018165-4D81B471-4FCF-44F7-913A-168DFBD0808C Q37461536-607EE006-4CB4-4979-83F1-324BC6A297A9 Q37562484-91C6521A-0316-4783-886D-70E9AF4AAF01 Q37623972-443E8CB7-3F4D-4846-A946-C88D60143824 Q37668253-367FB4D8-CA8A-4058-A394-082A21B62D71 Q37672448-4A1F0634-F890-490A-A706-07C2CEDF0E7E Q37737458-26B1D10A-9221-4E1F-A0E4-D5F9F5C4A30E Q38371524-AC94354E-F90A-424B-8253-3053AEA139FB Q38383470-833D2B6C-90EE-4B9C-99E9-AE2CD7F6893E Q39022309-99715E34-8E92-4891-AEB2-63E21805068A Q39824145-C20CCEB8-3C39-49B9-9646-AD08399C5E7F Q40081685-5A9B2C99-0575-4E88-9724-529EC7B84CC0 Q42371759-6AD57F2E-D139-40C9-AF0C-A057FD891327 Q47148933-E5E31FCA-7787-4046-BC60-F7DA66A7BBBF Q47165470-4447CB32-EFC3-4B56-8DC1-C271C200E58A Q47174001-01E19DBD-1116-4A17-9375-2B4084DC1E42 Q47182784-7D22B9D7-025C-4869-82C7-CC2B84060BFD Q47192734-EA92F70F-37E5-4C88-8ADA-B19B81605485 Q47260852-DD01F12B-1370-4D1B-865F-9ABE2FF0BDFF Q48360915-0A990DBB-B96B-4C06-ABC7-ED3BFE4530C1 Q49658111-35FF7D5C-48BF-48D6-9696-10BAD017705D Q50100476-49812FCF-2DDE-48BC-AEF2-8E652B202256 Q50145776-2DCF0819-95E8-4010-B13B-9032AC15997B Q51833661-ED3AB174-B18D-412E-8E13-FC74F6B01E42 Q55407978-AFEC95F6-DD55-4C35-A5A8-B5D0984F5CBA Q57814883-F078B230-DADD-41BA-8688-373D75E97DC9

P2860

Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q38573559

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Canagliflozin: a sodium glucos ...... t of type 2 diabetes mellitus.

@en

type

label

Canagliflozin: a sodium glucos ...... t of type 2 diabetes mellitus.

@en

prefLabel

Canagliflozin: a sodium glucos ...... t of type 2 diabetes mellitus.

@en

P1433

Q38573559-2D737B82-EBFA-4788-A09D-C666666C82D1

P1476

Q38573559-EACB2367-0BE5-4171-B5B1-747EFFE72DAC

P2093

Q38573559-0F0FA72F-C50D-49C9-A970-4FFA26FD4AF7

Q38573559-16766B16-9C86-4C4B-BD2C-D28557D67D5E

Q38573559-4CD7108A-4119-42F1-AD8A-5B22053D258F

Q38573559-74CB3C14-9F02-4B1C-8AD8-A6FD973D881B

Q38573559-774A496B-96BB-49FB-B62F-C1A65291C603

Q38573559-824ED184-3649-470B-B87E-872D1D03B163

Q38573559-8ACD433A-B466-4556-9CEE-E74C0E9A52E9

Q38573559-9AA30A21-04CA-43D2-B60A-EF61FF26EC15

Q38573559-AC0C4B19-78CA-4FB6-AD4F-A8A23B77E1C5

Q38573559-B5556D71-5833-4212-9270-C95D38AFC4B7

P2860

Q38573559-028B9E56-F984-4EFF-84DB-14F4FEFBBA10

Q38573559-043DEC19-40C7-486C-A750-C49CFE103BCC

Q38573559-060687FE-8F00-43FB-8DF5-3CEB73B26230

Q38573559-1DB1813F-0470-46B1-9D71-B382585A3B3A

Q38573559-1EDF1778-8C4A-49A1-A179-2EE5847F1E68

Q38573559-1F8BD285-1300-42DC-949B-6F61DC54D098

Q38573559-205865A6-A7D6-4D59-A32E-E9C153D3FC2D

Q38573559-22779B78-448B-4369-84CB-111C00E07753

Q38573559-2B77A95D-A702-4A18-90F7-4423764180CF

Q38573559-35F94514-ED93-4118-A5DD-C6465A44D5B1

P304

Q38573559-84E6E8FF-EB24-4F23-852F-2C3FB34DB843

P31

Q38573559-5B51962C-D643-4D9B-AEC9-DEDA55E78845

P356

Q38573559-DA917D7D-47A6-40D4-8AF7-D0621D8A3021

P407

Q38573559-17C82122-FF88-43C5-98E3-CC33B9531CD8

P478

Q38573559-61971427-910D-4DCE-8940-31528202D2C9

P577

Q38573559-FC4DD8C0-D443-4BFC-B11F-6595F59F0225

P698

Q38573559-8D87B1CF-5826-44CE-9FCE-1271A61DA949

P921

Q38573559-003A90DC-2444-49E6-9101-1CDE76464699

P356

P1433

Annals of the New York Academy of Sciences

P1476

Canagliflozin: a sodium glucos ...... t of type 2 diabetes mellitus.

@en

P2093

Dainius Balis

http://www.w3.org/2001/XMLSchema#string

David Polidori

http://www.w3.org/2001/XMLSchema#string

Frank Vercruysse

http://www.w3.org/2001/XMLSchema#string

Gary Meininger

http://www.w3.org/2001/XMLSchema#string

Keith Demarest

http://www.w3.org/2001/XMLSchema#string

Kirk Ways

http://www.w3.org/2001/XMLSchema#string

Maria Alba

http://www.w3.org/2001/XMLSchema#string

Mehul Desai

http://www.w3.org/2001/XMLSchema#string

Nicholas Di Prospero

http://www.w3.org/2001/XMLSchema#string

Norm Rosenthal

http://www.w3.org/2001/XMLSchema#string

P2860

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

Standards of medical care in diabetes--2012

Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans.

Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.

SGLT2 inhibition--a novel strategy for diabetes treatment.

Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.

P304

28-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/NYAS.12852

http://www.w3.org/2001/XMLSchema#string

P407

P478

1358

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26305874

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes